Apogee Therapeutics (APGE) Short-term Investments (2023 - 2026)

Apogee Therapeutics (APGE) has reported Short-term Investments for 4 consecutive years, with $608.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 49.63% year-over-year to $608.1 million; the TTM figure through Mar 2026 stood at $608.1 million (up 49.63% YoY), while the FY2025 annual figure was $598.6 million, up 58.01% from the prior year.
• Short-term Investments rose to $608.1 million in Q1 2026 per APGE's latest filing, from $598.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $608.1 million in Q1 2026 and bottomed at $234.6 million in Q3 2023.
• Historically, Short-term Investments has averaged $401.0 million across 4 years, with a median of $381.2 million in 2025.
• Annual changes were most pronounced in 2024 — Short-term Investments jumped 73.63% — and 2025, when it grew 2.96%.
• Apogee Therapeutics' Short-term Investments stood at $277.1 million in 2023, then jumped by 36.7% to $378.9 million in 2024, then surged by 58.01% to $598.6 million in 2025, then climbed by 1.58% to $608.1 million in 2026.
• Business Quant data shows APGE's Short-term Investments at $608.1 million in Q1 2026, $598.6 million in Q4 2025, and $419.4 million in Q3 2025.